



## New Technology Add-on Payment (NTAP) for Inpatient Claims (FY2023) Tool

HCP/CS Code	Drug-Generic	Drug Brand	FDA Newness Start Date	NTAP Start date	Status FY 2023 (eff. 10/1/22)	FY2023 Max Payment	Required Code Type	Required Code
Q2056	Ciltacabtagene autoleuce	Carvykti	02/28/2022	10/01/2022	New	\$289,532.75	ICD-10-PCS Code	XW033A7, XW043A7
J9144	Daratumumab and hyaluronidase-fihj	Darzalex Faspro	01/15/2021	10/01/2022	New	\$5,159.41	ICD-10-PCS Code	XW01318 in combination with E85.81
C9399 or J8499	Maribavir	Livtency	11/23/2021	10/01/2022	New	\$32,500.00	ICD-10-PCS Code	XW0DX38, XW0G738, XW0H738
C9399	Taurolidine and heparin	DefenCath	TBD	Must meet marketing by 7/1/2023	Conditional Approval	\$4,387.50	ICD-10-PCS Code	XY0YX28
Q2055	Idecabtagene vicleucel	Abecma	3/26/2021	10/01/2021	Continue	\$289,532.75	ICD-10-PCS Code	XW033K7, XW043K7
J1448	Trilaciclib	Cosela	2/12/2021	10/01/2021	Continue	\$5,612.10	ICD-10-PCS Code	XW03377, XW04377
J0699	Cefiderocol	Fetroja (HABP/VABP)	9/25/2020	10/01/2021	Continue	\$8,579.84	ICD-10-PCS Code	XW033A6 or XW043A6 in combination with ICD-10-CM code Y95 and one of the following: J14, J15.0, J15.1, J15.5, J15.6, J15.8, OR XW033A6 or XW043A6 in combination with J95.851 and one of the following: B96.1, B96.20, B96.21, B96.22, B96.23, B96.29, B96.3, B96.5, or B96.89
J0742	Imipenem/Cilastatin/relebactam	Recarbrio (HABP/VABP)	06/04/2020	10/01/2021	Continue	\$9,576.51	ICD-10-PCS Code	XW033U5 or XW043U5 in combination with ICD-10-CM code Y95 and one of the following: J14, J15.0, J15.1, J15.5, J15.6, J15.8, OR XW033U5 or XW043U5 in combination with J95.851 and one of the following: B96.1, B96.20, B96.21, B96.22, B96.23, B96.29, B96.3, B96.5, or B96.89
J9061	Amivantamab	Rybrevant	5/21/2021	10/01/2021	Continue	\$6,405.89	ICD-10-PCS Code	XW033B7, XW043B7
Q2053	Brexucabtagene autoleucel	Tecartus	7/24/2020	10/01/2021	Continue	\$259,350.00	ICD-10-PCS Code	XW033M7, XW043M7
J0248	Remdesivir	Veklury	7/1/2020	11/02/2020	Continue	\$2,028.00	ICD-10-PCS Code	XW033E5, XW043E5
J9223	Lurbinectedin	Zepzelca	6/15/2020	10/01/2021	Continue	\$9,145.50	ICD-10-PCS Code	XW03387, XW04387
J7169	Andexanet alfa	Andexxa	05/03/2018	10/01/2018	Discontinue	\$18,281.25	ICD-10-PCS Code	XW03372, XW04372
A9590	Ultratrace iobenguane Iodine-131	Azedra	5/21/2019	10/01/2019	Discontinue	\$98,150.00	ICD-10-PCS Code	XW033S5, XW043S5
C9399 or J8999	Erdafitinib (PO chemotherapy)	Balversa	4/12/2019	10/19/2019	Discontinue	\$3,563.23	ICD-10-PCS Code	XW0DXL5
C9047	Caplacizumab-yhdp	Cablivi	02/06/2019	10/01/2019	Discontinue	\$33,215.00	ICD-10-PCS Code	XW013W5, XW033W5, XW043W5
J9269	Tagraxofusp-erzs	Elzonris	12/21/2018	10/01/2019	Discontinue	\$144,116.04	ICD-10-PCS Code	XW033Q5, XW043Q5
J0699	Cefiderocol	Fetroja	2/24/2020	10/2020	Discontinue	\$7,919.86	ICD-10-PCS Code	XW033A6, XW043A6
J9173	Durvalumab	Imfinzi	03/27/2020	10/01/2020	Discontinue	\$6,875.90	ICD-10-PCS Code	XW03336, XW04336
C9399 or J8499	Ruxolitinib (PO)	Jakafi	5/24/2019	10/01/2019	Discontinue	\$4,475.38	ICD-10-PCS Code	XW0DXT5
J0121	Omadacycline	Nuzyra	2/1/2019	10/01/2020	Discontinue	\$1,552.50	ICD-10-PCS Code	XW033B6, XW043B6
J0742	Imipenem/Cilastatin/relebactam	Recarbrio	1/6/2020	10/2020	Discontinue	\$3,532.78	ICD-10-PCS Code	XW033U5, XW043U5
J1300	Ecuzumab	Soliris	6/27/2019	10/2020	Discontinue	\$21,199.75	ICD-10-PCS Code	XW033C6, XW043C6
C9399 or J3490	Esketamine (Nasal)	Spravato	03/05/2019	10/01/2019	Discontinue	\$1,014.79	ICD-10-PCS Code	XW097M5
J9022	Atezolizumab	Tecentriq	03/18/2019	10/01/2020	Discontinue	\$6,875.90	ICD-10-PCS Code	XW033D6, XW043D6
J0691	Lefamulin	Xenleta	9/10/2019	10/2020	Discontinue	\$1,275.75	ICD-10-PCS Code	XW03366, XW04366, XW0DX66
C9399 or J8999	Gilteritinib (PO chemotherapy)	Xospata	11/28/2018	10/01/2019	Discontinue	\$7,312.50	ICD-10-PCS Code	XW0DXV5
J0291	Plazomicin	Zemdri	06/25/2018	10/01/2018	Discontinue	\$4,083.75	ICD-10-PCS Code	XW033G4, XW043G4
J0695	Ceftolozane/tazobactam	Zerbaxa	6/3/2019	10/2020	Discontinue	\$1,836.98	ICD-10-PCS Code	XW03396, XW04396
Q2054	Lisocabtagene maraleucel	Breyanzi	2/21/2021	N/A	Denied	N/A	ICD-10-PCS Code	XW033N7, XW043N7
C9399	Satralizumab-mwge	Enspryng	8/24/2020	08/2020	Denied	N/A	ICD-10-PCS Code	XW01397
J1823	Inebilizumab-cdon	UPLIZNA	07/09/2020	N/A	Denied	N/A	ICD-10-PCS Code	XW03398, XW04398

### Disclaimer:

The Pharmacy Revenue Cycle internet web site provides "hyperlinks" to other internet web sites that contain information created, published, maintained or otherwise posted by institutions or organizations independent of the developers of the Pharmacy Revenue Cycle website. We do not endorse, approve, certify or control those external web sites, and we do not guarantee the accuracy, completeness, efficacy or timeliness of information located at those sites. Use of any information obtained from those web sites is voluntary, and reliance on that information should only be undertaken after an independent review of its accuracy. "Tools" are posted as pdf files with a date stamp to preserve the time-sensitivity of the external information that was used to develop the tool. Use of our "Tools" is voluntary and the information should be independently reviewed for accuracy and applicability to your situation.

## New Technology Add-on Payment (NTAP) for Inpatient Claims (FY2023) Tool

Drug-Generic	ICD-10-PCS Effective Date	ICD -10-PCS Code	Description
Plazomicin	10/1/2018	XW033G4	Introduction of Plazomicin anti-infective into peripheral vein, percutaneous approach, new technology group 4
	10/1/2018	XW043G4	Introduction of Plazomicin anti-infective into central vein, percutaneous approach, new technology group 4
Andexanet alfa	10/1/2019	XW03372	Introduction of Andexanet alfa, Factor Xa inhibitor reversal agent into peripheral vein, percutaneous approach, new technology group 2
	10/1/2019	XW04372	Introduction of Andexanet alfa, Factor Xa inhibitor reversal agent into central vein, percutaneous approach, new technology group 2
Ultratrace iobenguane Iodine-131	10/1/2019	XW033S5	Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
	10/1/2019	XW043S5	Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
Caplacizumab-yhdp	10/1/2019	XW013W5	Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
	10/1/2019	XW033W5	Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
	10/1/2019	XW043W5	Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5
Tagraxofusp-erzs	10/1/2019	XW033Q5	Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
	10/1/2019	XW043Q5	Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
Erdafitinib	10/1/2019	XW0DXL5	Introduction of Erdafitinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
Esketamine	10/1/2020	XW097M5	Introduction of Esketamine Hydrochloride into nose, via natural or artificial opening, new technology group 5
Gilteritinib	10/1/2019	XW0DXV5	Introduction of Gilteritinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
Ruxolitinib	10/1/2019	XW0DXT5	Introduction of Ruxolitinib into Mouth and Pharynx, External Approach, New Technology Group 5
Durvalumab	10/1/2020	XW03336	Introduction of durvalumab antineoplastic into peripheral vein, percutaneous approach, new technology group 6
	10/1/2020	XW04336	Introduction of durvalumab antineoplastic into central vein, percutaneous approach, new technology group 6
Atezolizumab	10/1/2020	XW033D6	Introduction of atezolizumab antineoplastic into peripheral vein, percutaneous approach, new technology group 6
	10/1/2020	XW043D6	Introduction of atezolizumab antineoplastic into central vein, percutaneous approach, new technology group 6
Eculizumab	10/1/2020	XW033C6	Introduction of eculizumab into peripheral vein, percutaneous approach, new technology group 6
	10/1/2020	XW043C6	Introduction of eculizumab into central vein, percutaneous approach, new technology group 6
Cefiderocol	10/1/2020	XW033A6	Introduction of cefiderocol into peripheral vein, percutaneous approach, new technology group 6
	10/1/2020	XW043A6	Introduction of cefiderocol into central vein, percutaneous approach, new technology group 6
Omadacycline	10/1/2020	XW033B6	Introduction of omadacycline anti-infective into peripheral vein, percutaneous approach, new technology group 6
	10/1/2020	XW043B6	Introduction of omadacycline anti-infective into peripheral vein, percutaneous approach, new technology group 6
Imipenem/Cilastatin/relebactam	10/1/2019	XW033U5	Introduction of imipenem-cilastatin-relebactam anti-infective into peripheral vein, percutaneous approach, new technology group 5
	10/1/2019	XW043U5	Introduction of imipenem-cilastatin-relebactam anti-infective into central vein, percutaneous approach, new technology group 5
Lefamulin	10/1/2020	XW03366	Introduction of lefamulin anti-infective into peripheral vein, percutaneous approach, new technology group 6
	10/1/2020	XW04366	Introduction of lefamulin anti-infective into central vein, percutaneous approach, new technology group 6
	10/1/2020	XW0DX66	Introduction of lefamulin anti-infective into mouth and pharynx, external approach, new technology group 6
Ceftolozane/tazobactam	10/1/2020	XW03396	Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
	10/1/2020	XW04396	Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
Amivantamab	10/1/2021	XW033B7	Introduction of amivantamab monoclonal antibody into peripheral vein, percutaneous approach, new technology group 7
	10/1/2021	XW043B7	Introduction of amivantamab monoclonal antibody into central vein, percutaneous approach, new technology group 7

### Disclaimer:

The Visante Pharmacy Revenue Cycle internet web site provides "hyperlinks" to other internet web sites that contain information created, published, maintained or otherwise posted by institutions or organizations independent of the developers of the Visante Pharmacy Revenue Cycle website. We do not endorse, approve, certify or control those external web sites, and we do not guarantee the accuracy, completeness, efficacy or timeliness of information located at those sites. Use of any information obtained from those web sites is voluntary, and reliance on that information should only be undertaken after an independent review of its accuracy. "Tools" are posted as pdf files with a date stamp to preserve the time-sensitivity of the external information that was used to develop the tool. Use of our "Tools" is voluntary and the information should be independently reviewed for accuracy and applicability to your situation.

## New Technology Add-on Payment (NTAP) for Inpatient Claims (FY2023) Tool

Lisocabtagene maraleucel	10/1/2021	XW033N7	Introduction of lisocabtagene maraleucel immunotherapy into peripheral vein, percutaneous approach, new technology group 7
	10/1/2021	XW043N7	Introduction of lisocabtagene maraleucel immunotherapy into central vein, percutaneous approach, new technology group 7
Trilaciclib	10/1/2021	XW03377	Introduction of trilaciclib into peripheral vein, percutaneous approach, new technology group 7
	10/1/2021	XW04377	Introduction of trilaciclib into central vein, percutaneous approach, new technology group 7
Satralizumab-mwge	10/1/2021	XW01397	Introduction of satralizumab-mwge into subcutaneous tissue, percutaneous approach, new technology Group 7
Idecabtagene vicleucel	10/1/2021	XW033K7	Introduction of idecabtagene vicleucel immunotherapy into peripheral vein, percutaneous approach, new technology group 7
	10/1/2021	XW043K7	Introduction of idecabtagene vicleucel immunotherapy into central vein, percutaneous approach, new technology group 7
Brexucabtagene autoleucel	10/1/2021	XW033M7	Introduction of brexucabtagene autoleucel Immunotherapy into peripheral vein, percutaneous approach, new technology group 7
	10/1/2021	XW043M7	Introduction of brexucabtagene autoleucel Immunotherapy into central vein, percutaneous approach, new technology group 7
Remdesivir	11/2/2020	XW033E5	Introduction of remdesivir anti-infective into peripheral vein, percutaneous approach, new technology group 5
		XW043E5	Introduction of remdesivir anti-infective into central vein, percutaneous approach, new technology group 5
Lurbinectedin	10/1/2021	XW03387	Introduction of lurbinectedin into peripheral vein, percutaneous approach, new technology group 7
	10/1/2021	XW04387	Introduction of lurbinectedin into central vein, percutaneous approach, new technology group 7
Daratumumab and hyaluronidase-fihj	10/1/2022	XW01318	Introduction of daratumumab and hyaluronidase-fihj into subcutaneous tissue, percutaneous approach, new technology group 8
Maribavir	10/1/2022	XW0DX38	Introduction of maribavir anti-infective into mouth and pharynx, external approach, new technology group 8
		XW0G738	Introduction of maribavir anti-infective into upper gi, via natural or artificial opening, new technology group 8
		XW0H738	Introduction of maribavir anti-infective into lower gi, via natural or artificial opening, new technology group 8
Carvykti	10/1/2022	XW033A7	Introduction of ciltacabtagene autoleucel into peripheral vein, percutaneous approach, new technology group 7
		XW043A7	Introduction of ciltacabtagene autoleucel into central vein, percutaneous approach, new technology group 7
DefenCath	10/1/2022	XY0YX28	Extracorporeal introduction of taurolidine antiinfective and heparin anticoagulant, new technology group 8
Inebilizumab-cdon	10/1/2022	XW03398	Introduction of inebilizumab-cdon into peripheral vein, percutaneous approach, new technology group 8
		XW04398	Introduction of inebilizumab-cdon into central vein, percutaneous approach, new technology group 8

### Disclaimer:

The Visante Pharmacy Revenue Cycle internet web site provides "hyperlinks" to other internet web sites that contain information created, published, maintained or otherwise posted by institutions or organizations independent of the developers of the Visante Pharmacy Revenue Cycle website. We do not endorse, approve, certify or control those external web sites, and we do not guarantee the accuracy, completeness, efficacy or timeliness of information located at those sites. Use of any information obtained from those web sites is voluntary, and reliance on that information should only be undertaken after an independent review of its accuracy. "Tools" are posted as pdf files with a date stamp to preserve the time-sensitivity of the external information that was used to develop the tool. Use of our "Tools" is voluntary and the information should be independently reviewed for accuracy and applicability to your situation.